ES2960717T3 - [9,10-Dimetoxi-3-(2-metilpropil)-1H,2H,3H,4H,6H,7H,11BH-pirido-[2,1-A]isoquinolin-2-il]metanol y compuestos, composiciones y métodos relacionados con el mismo - Google Patents
[9,10-Dimetoxi-3-(2-metilpropil)-1H,2H,3H,4H,6H,7H,11BH-pirido-[2,1-A]isoquinolin-2-il]metanol y compuestos, composiciones y métodos relacionados con el mismo Download PDFInfo
- Publication number
- ES2960717T3 ES2960717T3 ES16705684T ES16705684T ES2960717T3 ES 2960717 T3 ES2960717 T3 ES 2960717T3 ES 16705684 T ES16705684 T ES 16705684T ES 16705684 T ES16705684 T ES 16705684T ES 2960717 T3 ES2960717 T3 ES 2960717T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562113316P | 2015-02-06 | 2015-02-06 | |
| PCT/US2016/016892 WO2016127133A1 (en) | 2015-02-06 | 2016-02-05 | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2960717T3 true ES2960717T3 (es) | 2024-03-06 |
Family
ID=55404854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16705684T Active ES2960717T3 (es) | 2015-02-06 | 2016-02-05 | [9,10-Dimetoxi-3-(2-metilpropil)-1H,2H,3H,4H,6H,7H,11BH-pirido-[2,1-A]isoquinolin-2-il]metanol y compuestos, composiciones y métodos relacionados con el mismo |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9714246B2 (OSRAM) |
| EP (1) | EP3253752B1 (OSRAM) |
| JP (1) | JP6755254B2 (OSRAM) |
| KR (1) | KR102586138B1 (OSRAM) |
| CN (1) | CN107438606B (OSRAM) |
| AU (1) | AU2016215033B2 (OSRAM) |
| CA (1) | CA2974540C (OSRAM) |
| ES (1) | ES2960717T3 (OSRAM) |
| IL (1) | IL253704B (OSRAM) |
| MX (1) | MX375718B (OSRAM) |
| RU (1) | RU2736509C2 (OSRAM) |
| WO (1) | WO2016127133A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296683B2 (en) | 2014-01-21 | 2023-12-01 | Neurocrine Biosciences Inc | Preparations for the treatment of congenital adrenal hyperplasia |
| WO2016127133A1 (en) | 2015-02-06 | 2016-08-11 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| ES2972600T3 (es) | 2015-10-30 | 2024-06-13 | Neurocrine Biosciences Inc | Sales de diclorhidrato de valbenazina y polimorfos de las mismas |
| DK3394057T3 (da) | 2015-12-23 | 2022-04-11 | Neurocrine Biosciences Inc | Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat) |
| JP7199359B2 (ja) | 2017-01-27 | 2023-01-05 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| BR112020005373A2 (pt) | 2017-09-21 | 2020-09-24 | Neurocrine Biosciences Inc. | formulação de valbenazina em alta dosagem e composições, métodos e kits relacionados com valbenazina |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| SG11202003194YA (en) | 2017-10-10 | 2020-05-28 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| TW202011963A (zh) * | 2018-06-14 | 2020-04-01 | 美商紐羅克里生物科學有限公司 | Vmat2抑制劑化合物、組合物及其相關方法 |
| MA53239A (fr) | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences Inc | Procédés d'administration de certains inhibiteurs de vmat2 |
| EP3860599B1 (en) | 2018-10-04 | 2024-05-15 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| CN120284862A (zh) | 2018-12-07 | 2025-07-11 | 纽罗克里生物科学有限公司 | 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式 |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
| EP4606429A3 (en) | 2021-03-22 | 2025-12-03 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54125699A (en) * | 1978-03-17 | 1979-09-29 | Nippon Chemiphar Co Ltd | Preparation of ( ) dihydroprotoemetine |
| AU2004251829B2 (en) * | 2003-06-20 | 2009-12-17 | F. Hoffmann-La Roche Ag | Hexahydropyridoisoqinolines as DPP-IV inhibitors |
| AU2007317242B2 (en) * | 2006-11-08 | 2013-08-01 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
| RU2339363C2 (ru) | 2006-12-28 | 2008-11-27 | Лидия Ибрагимовна Гайсанова | Мазь "бунхо", обладающая противовоспалительным и регенерирующим действием |
| CN113368110A (zh) * | 2014-02-07 | 2021-09-10 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| WO2016127133A1 (en) | 2015-02-06 | 2016-08-11 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
-
2016
- 2016-02-05 WO PCT/US2016/016892 patent/WO2016127133A1/en not_active Ceased
- 2016-02-05 US US15/017,480 patent/US9714246B2/en active Active
- 2016-02-05 AU AU2016215033A patent/AU2016215033B2/en active Active
- 2016-02-05 JP JP2017541333A patent/JP6755254B2/ja active Active
- 2016-02-05 CN CN201680008945.5A patent/CN107438606B/zh active Active
- 2016-02-05 KR KR1020177024606A patent/KR102586138B1/ko active Active
- 2016-02-05 MX MX2017010062A patent/MX375718B/es active IP Right Grant
- 2016-02-05 CA CA2974540A patent/CA2974540C/en active Active
- 2016-02-05 ES ES16705684T patent/ES2960717T3/es active Active
- 2016-02-05 RU RU2017130514A patent/RU2736509C2/ru active
- 2016-02-05 EP EP16705684.5A patent/EP3253752B1/en active Active
-
2017
- 2017-06-19 US US15/627,145 patent/US9988382B2/en active Active
- 2017-07-27 IL IL253704A patent/IL253704B/en active IP Right Grant
-
2018
- 2018-04-30 US US15/967,187 patent/US20180273533A1/en not_active Abandoned
-
2020
- 2020-01-22 US US16/748,999 patent/US11053242B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017010062A (es) | 2017-11-01 |
| CA2974540A1 (en) | 2016-08-11 |
| NZ733899A (en) | 2024-01-26 |
| US11053242B2 (en) | 2021-07-06 |
| RU2736509C2 (ru) | 2020-11-17 |
| AU2016215033A1 (en) | 2017-08-10 |
| EP3253752C0 (en) | 2023-08-16 |
| KR102586138B1 (ko) | 2023-10-05 |
| WO2016127133A1 (en) | 2016-08-11 |
| JP6755254B2 (ja) | 2020-09-16 |
| CA2974540C (en) | 2023-09-26 |
| IL253704B (en) | 2021-02-28 |
| RU2017130514A (ru) | 2019-03-07 |
| RU2017130514A3 (OSRAM) | 2019-08-27 |
| US9714246B2 (en) | 2017-07-25 |
| KR20170113620A (ko) | 2017-10-12 |
| US9988382B2 (en) | 2018-06-05 |
| US20200262834A1 (en) | 2020-08-20 |
| CN107438606B (zh) | 2020-09-18 |
| MX375718B (es) | 2025-03-06 |
| EP3253752A1 (en) | 2017-12-13 |
| IL253704A0 (en) | 2017-09-28 |
| JP2018504437A (ja) | 2018-02-15 |
| BR112017016934A2 (pt) | 2018-04-03 |
| US20160289226A1 (en) | 2016-10-06 |
| CN107438606A (zh) | 2017-12-05 |
| US20170349586A1 (en) | 2017-12-07 |
| US20180273533A1 (en) | 2018-09-27 |
| AU2016215033B2 (en) | 2020-06-25 |
| EP3253752B1 (en) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2960717T3 (es) | [9,10-Dimetoxi-3-(2-metilpropil)-1H,2H,3H,4H,6H,7H,11BH-pirido-[2,1-A]isoquinolin-2-il]metanol y compuestos, composiciones y métodos relacionados con el mismo | |
| ES2915266T3 (es) | Derivados de N-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarínico 4 (M4) para el tratamiento de enfermedades neurológicas | |
| EA036672B1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| ES2927352T3 (es) | Inhibidores selectivos de HDAC6, método de preparación de los mismos y aplicación de los mismos | |
| ES2719626T3 (es) | Moduladores alostéricos positivos al receptor M1 muscarínico | |
| JP7623294B2 (ja) | 化合物、組成物および方法 | |
| BR112017016934B1 (pt) | Compostos inibidores do transportador vesicular de monoamina 2 (vmat2), composição farmacêutica compreendendo os mesmos, uso dos mesmos para tratar um transtorno hipercinético, esquizofrenia e transtorno bipolar e método para preparar a dita composição farmacêutica | |
| ES3032498T3 (en) | Vmat2 inhibitors and methods of use | |
| JP2003081978A (ja) | スピロ環式化合物およびその医薬用途 | |
| HK40092922B (en) | Vmat2 inhibitors and methods of use | |
| HK40092922A (en) | Vmat2 inhibitors and methods of use | |
| HK40069073B (en) | Compounds, compositions and methods |